
April 2 (Reuters) - AC Immune SA ACIU.O:
AC IMMUNE SA - ACI-7104.056 IS WELL TOLERATED WITH NO SAFETY ISSUES REPORTED TO DATE
AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE